Clinical trial · Observational
Clinical Cohort of Lymphoma Patients in Malawi
LCCC 1229: Developing a Prospective Lymphoma Clinical Cohort in Malawi
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
This registry study is intended to establish a large prospective longitudinal clinical cohort of lymphoma patients in Malawi, as such data is currently lacking from sub-Saharan Africa. The investigators will perform core biopsies on at least 800 consecutively enrolled patients with suspected lymphoma for accurate histopathologic characterization. The investigators will systematically collect relevant clinical and laboratory data, and longitudinally follow those with confirmed hematologic malignancies receiving treatment according to local standards of care to assess outcomes.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hematologic Malignancies | Hematopoietic and Lymphoid Cell Neoplasm | ALIAS | 0.90 |
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Lymphoma
- description
- Suspected lymphoma with confirmed hematologic malignancies treated under local conditions
Primary outcomes (1)
- measure
- Number of patients with suspected lymphoma
- timeFrame
- 5 years
- description
- At the time of initial assessment, all patients will undergo diagnostic lymph node biopsy.
Secondary outcomes (7)
- measure
- Number of patients with Epstein-Barr virus (EBV)
- timeFrame
- 5 years
- description
- Core biopsy specimens will be tested for the presence of EBV and extra serum sample at enrollment, mid-treatment, treatment completion, and 6 months to allow EBV viral load
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Criteria: Inclusion Criteria: * Referred to Kamuzu Central Hospital (KCH) with clinically suspected lymphoma based on clinical impression of referring providers Age \>5 years, or ≤5 years only if lymphoma has already been pathologically confirmed. * No prior or concurrent histologically confirmed cancer diagnosis or receipt of cancer treatment. * Residence \<200 kilometers from KCH. Able to understand and comply with study procedures for the entire length of the study, with assistance of parent or guardian as applicable. * Subject (or parent or guardian as applicable) able to understand and provide written consent in English or Chichewa. * Informed consent reviewed and signed by patient, or for pediatric patients, from parent or guardian. Exclusion Criteria: * There are no exclusion criteria other than failure to meet inclusion criteria listed above. * Patients may consent to participation in the study but refuse directed genomic analysis of their lymphoma specimens.
References
Publications (2)
- DERIVEDGondwe Y, Kudowa E, Tomoka T, Kasonkanji ED, Kaimila B, Zuze T, Mumba N, Kimani S, Mulenga M, Chimzimu F, Kampani C, Randall C, Lilly A, Gopal S, Fedoriw Y, Painschab M. Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy. PLoS One. 2022 Sep 1;17(9):e0273408. doi: 10.1371/journal.pone.0273408. eCollection 2022. PMID 36048901
- DERIVEDKaimila B, van der Gronde T, Stanley C, Kasonkanji E, Chikasema M, Tewete B, Fox P, Gopal S. Salvage chemotherapy for adults with relapsed or refractory lymphoma in Malawi. Infect Agent Cancer. 2017 Aug 9;12:45. doi: 10.1186/s13027-017-0156-3. eCollection 2017. PMID 28808480